Table 3. Clinical characteristics of 27 patients with non-CD5-T-cell marker-positive B-cell lymphoma.
| Case No. | Age/sex | Main site(s) of involvement | Stage | Extranodal involvement | Treatment | Response | Follow-up (months) | Status | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ≥ 1 | ≥ 2 | BM | ||||||||
| 1 | 64/M | Cecum | IIA | + | − | − | Sur + R-CHOP | CR | 68 | Alive, CR |
| 2 | 71/M | oral cavity | IIA | + | − | − | R-CHOP | NA | 64 | DOD |
| 3 | 77/M | mediastinum | IVB | + | + | − | R-CHOP | PD | 7 | NA |
| 4 | 66/F | axillary LN | IVB | + | + | − | R-CHOP + RT | PD | 24 | DOD, refractory |
| 5 | 41/M | tonsil, colon | III | + | + | − | R-CHOP | CR | 71 | Alive, CR |
| 6 | 44/F | cervical LN | IB | − | − | − | R-CHOP + RT | CR | 53 | Alive, CR |
| 7 | 74/F | oral cavity | I | + | − | − | R-CHOP | CR | 65 | Alive, CR |
| 8 | 58/M | BM, spleen | IVB | + | + | + | R-CHOP | CR | 15 | DOD, relapsed |
| 9 | 62/F | nasal cavity | IIA | + | − | − | R-CHOP | PR | 34 | AWD, relapsed |
| 10 | 58/M | inguinal LN | IVA | + | − | − | R-CHOP | CR | 52 | Alive, CR |
| 11 | 75/F | abdominal LN | IIIA | + | + | + | R-CHOP | PD | 2 | DOD, refractory |
| 12 | 60/M | maxillary sinus | I | + | − | − | R-CHOP | CR | 46 | Alive, CR |
| 13 | 81/M | Orbit | IA | + | − | − | R-CHOP | CR | 7 | Alive, CR |
| 14 | 67/M | abdominal LN | IVA | + | + | − | R-ICE | CR | 47 | Alive, CR |
| 15 | 62/M | cervical LN | IIIA | − | − | − | R-CHOP | CR | 71 | AWOD, relapsed |
| 16 | 60/M | parotid gland | IIA | + | − | − | R-CHOP | CR | 17 | Alive, CR |
| 17 | 78/F | abdominal LN | IV | + | − | − | R-CHOP | CR | 26 | AWD, relapsed |
| 18 | 82/M | nasal cavity | IA | + | − | − | R-CHOP | CR | 45 | Alive, CR |
| 19 | 64/M | Orbit | IB | + | − | − | R-DHAP | PD | 2 | DOD |
| 20 | 81/M | soft tissue (leg) | IVA | + | + | − | R-CHOP | CR | 40 | DOD, relapsed |
| 21 | 55/M | cervical LN | IVA | + | + | − | R-CHOP | CR | 12 | DOD, relapsed |
| 22 | 43/M | Gingiva | IA | + | − | − | R-CHOP | CR | 60 | Alive, CR |
| 23 | 78/M | Orbit | NA | + | + | NA | NA | NA | NA | NA |
| 24 | 65/M | Prostate | IVA | + | + | − | R-CHOP | CR | 49 | Alive, CR |
| 25 | 81/F | nasal cavity | IIA | + | + | − | R-CHOP | NA | 57 | DOD |
| 26 | 57/M | cervical LN | IA | − | − | − | R-CHOP + RT | CR | 87 | Alive, CR |
| 27 | 73/F | BM | IVB | + | + | + | R-CHOP | PD | 10 | DOD, refractory |
M, male; F, female; BM: bone marrow; LN, lymph node; Sur, surgery; RT, radiation therapy; CR, complete response; PD, progressive disease; PR, partial response; NA, not available; DOD, died of disease; AWD, alive with disease; AWOD, alive without disease; R-ICE, rituximab plus ifosfamide, etoposide, and carboplatinum; R-DHAP, rituximab plus dexamethasone, cytarabine, and cisplatinum.